Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01090921|
Recruitment Status : Completed
First Posted : March 23, 2010
Last Update Posted : February 2, 2016
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Bortezomib||Phase 2|
This study is a multi-site study which will enroll up to 50 patients with multiple myeloma who have not had prior treatment.
Prior to starting treatment individuals will be evaluated to determine if they are eligible to participate in the study. There are certain prestudy test that are required: physical exam, blood tests, ECG, chest x-ray, skeletal survey, bone marrow aspirate and biopsy to confirm the diagnosis of multiple myeloma and to determine baseline health status.
Before beginning each treatment cycle and at the end of the study, patients will have protein studies (including blood and urine) to see if they are responding to the treatment. Before each weekly treatment cycle patients will also have blood tests for red and white blood cells and platelets, and blood chemistry tests for electrolytes, kidney and liver function, calcium and blood sugar.
Patients may receive up to 6 cycles of treatment. At the end of the study, individuals who have responded to treatment will be seen every two months to check for disease progression.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma|
|Study Start Date :||May 2007|
|Primary Completion Date :||March 2015|
|Study Completion Date :||March 2015|
Bortezomib is administered at a dose of 1.6mg/m2 IV push over 3 to 5 seconds. Treatment is administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone is also administered at a dose of 40mg daily on day of and day after each dose of Bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone. The study duration for a given subject will be approximately 30 weeks.
Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.
Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone.
Other Name: Velcade
- To evaluate the objective response rate (CR + PR) to weekly bortezomib + dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for transplant or who are eligible but wish to postpone autologous stem cell transplant. [ Time Frame: Approximately 3 years ]
- To evaluate the toxicity (safety and tolerability) of weekly bortezomib + dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for transplant or who are eligible but wish to postpone autologous stem cell transplant. [ Time Frame: Approximately 3 years ]
- To evaluate time to progression and duration of response following bortezomib + dexamethasone treatment in patients with newly diagnosed multiple myeloma who are either ineligible or wish to postpone SCT. [ Time Frame: Approximately 3 years ]
- To collect blood and marrow samples for future analysis of molecular markers associated with response or resistance to bortezomib + dexamethasone in patients with newly diagnosed myeloma who are either ineligible or wish to postpone SCT. [ Time Frame: Approximately 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01090921
|United States, Arkansas|
|Little Rock VA Medical Center|
|Little Rock, Arkansas, United States, 72205|
|United States, California|
|West Los Angeles VA Medical Center|
|Los Angeles, California, United States, 90073|
|San Francisco VA Medical Center|
|San Francisco, California, United States, 94121|
|United States, Colorado|
|Eastern Colorado Health Care System|
|Denver, Colorado, United States, 80220|
|United States, Connecticut|
|West Haven VA Medical Center|
|West Haven, Connecticut, United States, 06516|
|United States, Florida|
|Tampa VA Medical Center|
|Tampa, Florida, United States, 33612|
|United States, Georgia|
|Atlanta VA Medical Center|
|Atlanta, Georgia, United States, 30033|
|United States, Massachusetts|
|VA Boston Healthcare System|
|Jamaica Plain, Massachusetts, United States, 02130|
|United States, Missouri|
|Kansas City VA Medical Center|
|Kansas City, Missouri, United States, 64128|
|United States, Pennsylvania|
|Pittsburgh VA Medical Center|
|Pittsburgh, Pennsylvania, United States, 15240|
|United States, Texas|
|Michael E. DeBakey VA Medical Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Nikhil C. Munshi, M.D.||Boston VA Research Institute, Inc.|
|Study Chair:||Saem Lee||Boston VA Research Institute, Inc.|